July 11, 2022 — BioSig Technologies, Inc., a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal fidelity through its proprietary signal processing platform, today announced that Kansas City Heart Institute at Overland Park Regional Medical Center in Kansas City, U.S. has signed a purchase agreement to acquire its PURE EP(T.M.) System.
Following its evaluation of BioSig's PURE EP System, Overland Park Regional Medical Center (OPRMC) has signed an agreement to purchase the technology under the terms of the Company's new program. The agreement represents BioSig's first commercial adoption since it announced the national launch of its PURE EP System, supported by The Company's new commercial structure and clinical support teams. The agreement also represents The Company's first national purchasing agreement.
"Establishing a contract with a leading national hospital network is a milestone achievement for BioSig Technologies," commented Gray Fleming, Chief Commercialization Officer, BioSig Technologies, Inc. "A leasing option provides a cost-effective and efficient pathway for hospitals to acquire our technology. As a Company that prioritizes physician experience and throughput, we believe a leasing program supports the clinical evolution of PURE EP as we continue upgrading and enhancing our technology based on physician feedback."
"We are pleased to announce our first purchase agreement since we transformed the commercial capabilities under new management," said Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc. "The Company is excited about our clinical collaboration with Dr. Lakkireddy and the physician faculty at Overland Park. As physician advocates, we are proud of our commitment to and alignment with the world-class arrhythmia program at Kansas City Heart Rhythm Institute and thank them for their continued support of our technology."
“This technology will be an instrumental part of Kansas City Heart Rhythm Institute’s continued quest to provide superior world class care for patients,” says Executive Medical Director for the Kansas City Heart Rhythm Institute and Professor of Medicine at the University of Missouri Columbia and University of Nevada Las Vegas and Chief of Electrophysiology at Overland Park Medical Center, Dhanunjaya DJ Lakkireddy, MD. “This technology could potentially enhance our ability to improve efficacy and safety of heart rhythm procedures and thereby positively impact workflow and subsequently, patient outcomes.”
For more information: www.biosig.com
April 12, 2022 
